SA
Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+35.0%
avg across 11 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+27.3%
same 11 filings, from disclosure
Filings, ttm
12
12 buys · 1 sells · 2 late
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$46.2M
shares × price, as filed
Last traded
Oct 26
Filed Oct 27
Median ADV $31.6M across their filed names
Impact on $10,000 · 12M
$15,239 (+52.4%)
S&P 500 $10,907 (+9.1%) · 43.3 pts ahead
Srinivas Akkaraju
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $92.5M
Sells $1.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
12 filings
Sector per market data · by filing · past 12 months
Most traded names
ALMSRecent filings
MLYSPURCHASE
Mineralys Therapeutics, Inc.
View filing →
$8.1M600,000 sh × $13.50
Exec Mar 13 2025
Filed Mar 17 2025 · 5:30 PM ET NGNEPURCHASE Neurogene Inc. View filing → $1.2M
46,770 sh across 3 lots
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET